Charles A. Rowland Jr., Director at Nabriva Therapeutics plc (NBRV), bought 53,000 shares at $1.31 ($69K) on 2018-12-24, disclosed to the SEC on 2018-12-27.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| VKTX | SELL | 2023-05-18 | $1.0M | — | Filing → |
| GBIO | BUY | 2022-09-20 | $83K | — | Filing → |
| GBIO | BUY | 2022-09-19 | $552K | — | Filing → |